title: Myricetin, a potent natural agent for treatment of diabetic skin damage by modulating TIMP/MMPs balance and oxidative stress.
abstract: Foot ulceration is a major cause of morbidity in patients with diabetes, and abnormal peripheral neuropathy often results in hospitalization. Up-regulation of matrix metalloproteinases and down-regulation of tissue inhibitor of metalloproteinase 1 are noted to be distinctive biological functions of diabetic dermal fibroblasts. The aim of this study was to evaluate the biological effects of modified retinoids on diabetic fibroblasts. Myricetin, a natural compound, balances the TIMP1/MMP ratio and oxidative stress in diabetic fibroblasts. Our results indicate that myricetin significantly ameliorates the effects of diabetes on dermal fibroblasts. In addition, we found that the oxidative stress imbalance induced by a high glucose concentration plays an important role in the changes to dermal fibroblasts that occur in diabetes. Our findings support the hypothesis that myricetin has the potential to repair faulty skin function arising from diabetes.
authors.affiliation: Tianjin Key Laboratory of Food Biotechnology, College of Biotechnology and Food Science, Tianjin University of Commerce, Tianjin, China.
authors.forename: Zijian
authors.initials: Z
authors.lastname: Wu
authors.affiliation: Tianjin Institute of Pharmaceutical Research, Tianjin, China.
authors.forename: Xuemin
authors.initials: X
authors.lastname: Zheng
authors.affiliation: Department of Pharmacy, Tianjin Medical University, Tianjin, China.|Department of Oncology, University of Oxford, Oxford, UK.
authors.forename: Min
authors.initials: M
authors.lastname: Gong
authors.affiliation: Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
mesh_terms: D048909:Diabetes Complications / Q000188:drug therapy*; D005260:Female; D005347:Fibroblasts / Q000187:drug effects; D005419:Flavonoids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D020782:Matrix Metalloproteinases / Q000032:analysis*; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D012871:Skin Diseases / Q000188:drug therapy*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000032:analysis*
chemical_list: D005419:Flavonoids; D019715:Tissue Inhibitor of Metalloproteinase-1; C040015:myricetin; D020782:Matrix Metalloproteinases
keywords: MMP; diabetic fibroblast; high glucose; myricetin; oxidative stress